Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 1, 2000 - Issue 3
Submit an article Journal homepage
260
Views
30
CrossRef citations to date
0
Altmetric
Review

Migraine pharmacotherapy with oral triptans: a rational approach to clinical management

David S Millson Department of Medicines Management, Keele University, Staffordshire, ST5 5BG, UK. [email protected]
,
Stewart J Tepper The New England Center for Headache, Stamford, Connecticut, USA
&
Alan M Rapoport Department of Medicines Management, Keele University, Staffordshire, ST5 5BG, UK. [email protected]
Pages 391-404 | Published online: 24 Feb 2005

Bibliography

  • FERRARI M: Migraine treatment: a review. Lancet (1998) 351:1043–1045.
  • •A general review of migraine treatments including the new triptans.
  • GOADSBY PJ: A triptan too far? J. Neurol. Neurosurg. Psychiatry (1998) 64:143–145.
  • ••An evidenced based review of triptans in clinicaldevelopment.
  • MILLSON DS: Do we need another triptan for the acute treatment of headache? J. Immunol. Immunopharmacol. (1998) 18:99–104.
  • TEPPER SJ, RAPOPORT AM: The triptans: a summary. CNS Drugs (1999) 12.:403–417.
  • ••A review of the safety, efficacy and clinical profiles of thetriptans.
  • O'QUINN S, JONES M, KANE K, THAVENTHIRAN L, SAIERS J: Naratriptan tablets 2.5mg exhibit prolonged action and are well tolerated in non-severe migraine attacks: data from a comparator study with sumatriptan. Neurol 52 (Suppl 2):A256
  • GALLAGHER RM: Comparison of zolmitriptan and sumatriptan for the acute treatment of migraine. Cephalalgia (1999) 19 (II-G1-14) :35.
  • SCHOENEN J, JONES M, KANE K, VAN ASSCHE P, SAIERS J: Naratriptan 2.5mg tablets have a similar efficacy in the acute treatment as zolmitriptan 2.5 mg tablets, but exhibit a longer duration of action and are better tolerated: results of a comparator study. ANN Toronto (1999) S32.005.
  • DIENER H, KLEIN K: A randomised placebo controlledcomparison of zolmitriptan 5.0mg with sumatriptan 100mg. 3rd European Headache Federation Meeting Sardinia, Italy (1996).
  • Rizatriptan MAXALT US Package Insert (1998).
  • MELOCHE J: Triptans and migraine: which drug for which patient? Can. J. Diagnosis (1999) 16(1):67–77.
  • ••An evidenced based review of the clinical profiles of thenew triptans.
  • DIXON CM, PARK GR, TARBIT MH: Characterisation of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem. Pharmacol. (1994) 47:1253–1257.
  • RANCE D, CLEAR N, DALIMAN et al.: Physicochemical comparison of eletriptan and other 5-HT1u like agonists as a predictor of oral absorption potential. Headache (1997) 37:328.
  • EVANS DC, O'CONNOR D. SCOTT-STEVENS P, BEER MS, TATTERSALL MJ, HARGREAVES RJ: Central sites of action are important for the antimigraine efficacy of triptan-5HT1Bi1D agonist. Proceedings of the 9th Interna-tional Headache Congress. Barcelona, Spain (22–26 June 1999). LMOP–3
  • GOADSBY PJ, HOSKIN KL: Inhibition of trigeminal neurones by intravenous administration of the 5HT1a/1D-receptor agonist zolmitriptan: are brain stem sites a therapeutic target in migraine. Pain (1996) 67:355–359.
  • •An important paper which describes the scientific basis for the use of centrally acting triptan in the treatment of migraine.
  • SEABER E, ON N, DIXON RM et al.: The absolute bioavail-ability and metabolic disposition of the novel antimi-graine compound zolmtriptan (311C90). Br. J. Clin. Pharmacol. (1997) 43:579–587.
  • ROLAN PE: Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia (1997) 17: (Supp1.18):21–27.
  • CATTAEU A, BECHTEL UC, POISSON N, BECHTEL PR, CONAITI-PELLIE C: A population and family study of CYP1A2 using caffeine urinary metabolites. Eur. J. Clin. Pharmacol. (1997) 47:423–30.
  • •An important paper which highlights the potential metabolic pathways involved in the bio-transformation and elimination of the triptans.
  • BUCHAN P: The pharmacokinetics of frovatriptan (VML 251/S9209509) a potent, selective 5-HT1ai1D agonist, following single dose administration by oral and intravenous routes to healthy male and female volunteers. Headache (1998) 38:376.
  • Zomig (Zolmitriptan): Summary of Product Characteristics. Marketing Authorisation PL 12619/0116 (1997).
  • ROGERS JD, LEE Y, GOLDBERG MR et al: Human pharmacokinetics or rizatriptan, a 5-HT1Bi1D receptor agonist. Func. Neurol. (1998) 13 (BC8):179.
  • VAN HAARST AD, GERVEN JMA, COHEN AF et al. The effects of moclobemide on the pharmacokinetics of the 5-HT1si1D receptor agonist rizatriptan in healthy volunteers. Br. J. Clin. Pharmacol. 48:190–196.
  • FUSEAU E. BAILLE P, KEMPSFORD R: A study to determine the absolute bioavailability of naratriptan. Cephalalgia 17:417. (Abstract).
  • Naramig (naratriptan hydrochloride). Summary of Product Characteristics. Marketing Authorisation RVG 21444 (1998).
  • MILTON KA, ALLEN MJ, ABEL S et al.: The safety, tolerability, pharmacokinetics and pharmacody-namics of oral and intravenous eletriptan, a potent and selective `5-HT1D-like' receptor partial agonist. Cephalalgia (1997) 17:414–415.
  • BUCHAN P, WARD C, FREESTONE S: Lack of interactionbetween frovatriptan and the monoamine oxidase inhibitor, moclobemide. Proceedings of the 9th Interna-tional Headache Congress. Barcelona, Spain (22–26 June 1999).
  • PARSONS A. PRAVIN R, SMITH S, TILFORD N, KING FD,KAUMANN AJ, HUNTER J. Effects of the novel high-affinity 5-HT1si1D-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J. Cardiovasc. Pharmacol 1998; 32:220–224.
  • ELKIND A, MCDARIS HL, SATIN L, KEYWOOD C: The cardiovascular safety of frovatriptan in patients at high risk of or with known coronary artery disease during a migraine attack. Proceedings of the 9th Interna-tional Headache Congress. Barcelona, Spain (22–26 June 1999). Abstract.
  • HOLM KJ, SPENCER CM: Almotriptan: ADIS new drugs profile. CNS Drugs (1999) 11:159–165.
  • FLEISHAKER JC, RYAN KK, CAREL BJ, AZIE NE: Effect of MAO-A inhibition on the pharmacokinetics of the novel anti-migraine agent, almotriptan, in humans. Proceedings of the 9th International Headache Congress. Barcelona, Spain (22–26 June 1999). P03.032
  • PFAFFENRATH V, CUNIN G, SJONELL G et al.: Efficacy and safety of Sumatriptan tablets (25 mg, 50 mg and 100 mg) in acute treatment of migraine: defining the optimal doses of oral sumatriptan . Headache (1998) 38:184.
  • FAZEKAS A: The efficacy, tolerability and safety or oral sumatriptan 50 mg in the acute treatment of migraine. Proceedings of the 8th International Headache Congress. (1997).
  • RAPOPORT AM, RAMADAN NM et al.: Optimising the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. Neurology (1997) 49:1210–1218.
  • SOLOMAN G: Dosing of oral sumatriptan - a review of our first 104 patients. Proceedings of the 8th International Headache Congress. (1997).
  • STEINER TJ ON BEHALF OF THE ELETRIPTAN STEERING COMMITTEE: Efficacy, safety and tolerability of oral eletriptan (40mg and 80mg) in the acute treatment of migraine: results of a Phase III study. Cephalalgia (1998) 18(6)385. (Abstract).
  • JACKSON NC FOR THE ELETRIPTAN STEERING COMMITTEE: A comparison of oral eletriptan (UK-116-044) (20–80 mg) and oral sumatriptan (100mg) in the acute treatment of migraine. Cephalal-gia (1996) 16(5):368. (Abstract).
  • KLASSEN A, ELKIND A, ASGHARNEJAD M, WEBSTER C, LAUREZA A: Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double blind, placebo-controlled, parallel-group study. Headache (1997) 37:640–645.
  • TEALL JH, TUCHMAN M, CUTLER N: Rizatriptan (maxalt) for the acute treatment of migraine and migraine recurrent. A placebo-controlled, outpatient study. Headache (1998) 38:281–287.
  • KRAMER MS: A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology (1998) 51:773–781.
  • VISSER WH, TEALL JH, MALBECQ W.: Early onset of action of rizatriptan versus Sumatriptan in the acute treatment of migraine. Headache Quarterly (1998) 9:264–275.
  • AHRENS SP, FARMER MV, WILLIAMS DL, WILLOUGHBY E, JIANG K, BLOCK GA, VISSER WH AND THE RIZATRIPTAN WAFER PROTOCOL 049 STUDY GROUP: Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia (1999) 19:525–530.
  • DAHLOF C, HOGENHUIS L, OLESEN J et al.: Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine; a dose ranging study. Eur. Neurol (1998) 5:469–477.
  • TFELT-HANSEN P, TEALL J, RODRIGUEZ F, GIACOVAZZO M, PAZ J, MALBECQ W, BLOCK GA, RIENES SA, VISSER WH ON BEHALF OF THE RIZATRIPTAN 030 STUDY GROUP: Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache (1998) 38:748–755.
  • FREITAG FG, DIAMOND ML, URBAN GJ, PEPPER B, MOORE K: The new treatments in migraine: first year clinical experience. American Association for the Study of Headache. Boston, USA (11–13 June 1999).
  • BORNHOF MK, LEGG N, PAZ J: Comparison of rizatriptan 10 mg versus naratriptan 2.5 mg in migraine. Headache (1999) 39:344. Poster no. 65.
  • JACKSON NC. On behalf of the Eletriptan steering committee. Clinical measures of efficacy, safety and tolerability for the acute treatment of migraine: a comparison of eletriptan (20-80mg), sumatriptan (100mg) and placebo. Neurology (1998) 50:A376.
  • PRYCE-PHILLIPS W ON BEHALF OF THE ELETRIPTAN STEERING COMMITTEE: Comparison of oral eletriptan (40-80mg) and oral sumatriptan (50–100mg) for the acute treatment of migraine: a randomised, placebo controlled trial in sumatriptan naive patients. Cephalalgia (1999) 19:355-356. Poster II-G1–6.
  • JACKSON NC: The clinical profile of eletriptan. Proceed-ings of the 9th International Headache Congress. Barcelona, Spain (22–26 June 1999). Platform presentation.
  • EDMEADS J, MILLSON DS: Tolerability profile of zolmitriptan, a novel dual central and peripherally acting 5HT1a/10 agonist: international clinical experi-ence based on 3000 subjects treated with zolmitriptan. Cephalalgia (1997) 17 (Suppl. 18) :41–52.
  • GIJSMAN H, KRAMER MS, SARGENT J et al: Double blind, placebo controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalal-gia (1997) 17(6):647–651.
  • MATHEW NT, KAILSAM F, MEADORS L, GENTRY P, CHERNYSHEV 0: Treatment of oral sumatriptan non-responders with 5mg zolmitriptan and 10mg rizatriptan: a comparative open trial. American Associa-tion for the Study of Headache. Boston, USA (11–13 June 1999).
  • MILLSON D, TEPPER SJ: Issues relating to the assess-ment of migraine recurrence following triptan therapy. Eur. J. Neurol. (1999) 6:1–2.
  • GOLDSTEIN J, RYAN R, JIANG K et al.: Crossover comparison of rizatriptan 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache (1998) 38:737–747.
  • PITMAN V, FOSTER E, JACKSON NJ: Comparison of oraleletriptan and oral sumatriptan for the acute treatment of migraine: combined analysis across three clinical trials. Headache (1999) 39:374. Abstract platform presentation.
  • DEINER HC, PASCUAL J, VEGA P: Comparison of rizatriptan 10mg versus zolmitriptan 2.5mg in migraine. American Association for the Study of Headache. Boston, USA (11–13 June 1999).

Websites

  • www.FDA.gov LEBER P: FDA Divisional Directorate recommendations for Maxalt (rizatriptan) tablet and RPD formulation. (1998) NDAs 20–864 and 20–865 page 3 of 8.
  • •A regulatory perspective on the issues raised by rizatriptan.
  • www.FDA.gov LEVIN R: Rizatriptan NDA. Neurology Team Leaders Review (June 1998) NDAs 20–864 page 180 f 20.
  • •Evidenced based review of the safety and efficacy data for rizatriptan which raises issues for the comparative evalua-tion of migraine therapies.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.